2004

研究業績

Papers (English)

Original papers

1. Edahiro S, Yoshikawa H, Iwasa K, Hashii M, Yamada M:Cytosolic Ca2+ alteration mediates both ryanodine receptor and IP3 receptor in TE671/RD cells. Biomed Res 25: 255-261, 2004

2. Furukawa Y, Matsumoto Y, Yamada M:Hypertrophic pachymeningitis as an initial and cardinal manifestation of microscopic polyangitis. Neurology 63:1722-1724, 2004

3. Ishida C, Furui E, Sakashita Y, Yamada M. Embolic stroke with a patent foramen ovale and Behet’s disease. Intern Med (In Press)

4. Ishida C, Kitamoto T, Yamada M:Sporadic Creutzfeldt-Jakob disease with MM1-type prion protein and plaques. Reply. Neurology 62:1239, 2004

5. Kamata T, Katsube K, Michikawa M, Yamada M, Takada S, Mizusawa H:R-spondin, a novel gene with thrombospondin type 1 domain, was expressed in the dorsal neural tube and affected in Wnts mutants. Biochim Biophys Acta (Gene Structure and Expression) 1676:51-62, 2004

6. Maruta T, Dolimbek BZ, Aoki KR, Steward LE, Atassi MZ:Mapping of the Synaptosome-Binding Regions on the Heavy Chain of Botulinum Neurotoxin A By Synthetic Overlapping Peptides Encompassing the Entire Chain. Protein J 23: 539-552, 2004

7. Nakamura Y, Watanabe M, Nagoshi K, Kitamoto T, Sato T, Yamada M, Mizusawa H, Maddox R, Sejvar J, Belay E, Schonberger LB. Update: Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts – Japan, 1979-2003. JAMA 291:295-296, 2004

8. Ono K, Hasegawa K, Naiki H, Yamada M:Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer’s β-amyloid fibrils in vitro. Biochim Biophys Acta (Molecular Basis of Disease) 1690:193-202, 2004

9. Ono K, Hasegawa K, Naiki H, Yamada M:Curcumin has potent anti-amyloidogenic effects for Alzheimer’s β-amyloid fibrils in vitro. J Neurosci Res 75:742-750, 2004

10. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M:Vitamin A exhibits potent anti-amyloidogenic and fibril-destabilizing effects in vitro. Exp Neurol 189:380-392, 2004

11. Sakai K , Komai K, Yanase D, Yamada M:Plasma VEGF as a marker for the diagnosis and treatment of vasculitic neuropathy. J Neurol Neurosurg Psychiatry 76:296, 2005

12. Shirasaki H, Yamaguchi K, Shima K, Murono S, Yamada M. Chronic inflammatory demyelinating polyradiculoneuropathy showing taste impairment. J Neurol Sci (In Press)

13. Takamori M, Motomura M, Kawaguchi N, Nemoto Y, Hattori T, Yochikawa H, Otsuka K: Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 62:1894-1896, 2004

14. Takamori M:Lambert-Eaton myasthenic syndrome as an autoimmune calcium channelopathy. Biochem Biophys Res Comm 322:1347-1351,2004

15. Yanase D, Komai K, Hamaguchi T, Okino S, Yokoji H, Makifuchi T, Takano H, Yamada M: Hereditary spastic paraplegia with frontal lobe dysfunction: a clinicopathologic study. Neurology 63:2149-2152, 2004

16. Yasukawa Y, Yoshikawa H, Iwasa K, Yamada M and Takamori M: Comparative study of preoperative thymic imaging and pathology in patients with myasthenia gravis. J Clin Neurosci 11: 610-613, 2004

17. Yoshinaga T, Takei Y, Katayanagi K, Ikeda S:Postmortem findings in a familial amyloid polyneuropathy patient with homozygosity of the mutant Val30/Met transthyretin gene. Amyloid: J Protein Folding Disord. 11:56-60, 2004

Reviews

1. Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO：Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer’s disease. Neurobiol Aging 25:589-597, 2004.

2. Taki J, Yoshita M, Yamada M, Tonami N.Significance of 123I-MIMG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: It can be a specific marker for Lewy body disease. Ann Nucl Med 18:453-461, 2004.

3. Yamada M：Cerebral amyloid angiopathy and gene polymorphisma. J Neurol Sci 226:41-44, 2004.

Presentations (International meeting)

Invited lectures

1. Takamori M, Kino T: Immunology of ryanodine receptor and FK 506 in myasthenia gravis. The 7th International Congress of Neuroimmunology. Venice, Italy, September 25-October 2, 2004

Presentations

1. Ishida C, Okino S, Kitamoto T, Yamada M. Involvement of the peripheral nervous system in human prion diseases including dural graft-associated Creutzfeldt-Jakob disease. International Symposium on Prion Diseases: Food and Drug Safety. Sendai Japan, October 31-November 2, 2004

2. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer’s disease. The 9th International Conference on Alzheimer’s Disease and Related Disorders. Philadelphia, July 17-22, 2004

3. Kohno T, Hirayama K, Iwatsuki R, Hirose M, Watabe K, Yoshikawa H, Matsumoto A, Fujita T, Hayashi M. Efficacy of a Novel Immunosuppressant FTY720 as a New Drug for Myasthenia Gravis. 7th International Congress of Neuroimmunology. Venice, Italy, 2004

4. Saito Y, Murayama S, Shimizu J, Hosino M, Takatsu M, Komatsuzaki Y, Nakano S, Arima K, Sasaki K, Takahashi K, Hara M, Hirayasu Y, Yamada M, Kanazawa I. Familial Creutzfeldt-Jakob disease with five octapeptide repeat insert International Symposium on Prion Diseases: Food and Drug Safety. Sendai Japan. October 31-November 2, 2004

5. Sato T, Masuda M, Utsumi Y, Enomoto S, Yamada M, Mizusawa H, Kitamoto T. Relationship between sites of grafts and initial clinical manifesatations in dura mater related Creutzfeldt-Jakob disease. International Symposium on Prion Diseases: Food and Drug Safety. Sendai Japan, October 31-November 2, 2004

6. Jha S, Wang H, Maruta T, Oshima M, Atassi MZ, Hoch W: Neurological disorder induced in mice by immunization with the muscle-specific kinase (MuSK). A model for myasthenia gravis? Society for Neuroscience 34th Annual Meeting. San Diego, October 23-27, 2004

7. Sodeyama N, Nakamura Y, Yamada M, Satoh T, Kitamoto T, Mizusawa H. Duration between initial manifestation of CJD and detection of PSD, specific findings on MRI, CSF 14-3-3 protein, or CSF high NSE. International Symposium on Prion Diseases: Food and Drug Safety. Sendai Japan, October 31-November 2, 2004

8. Hamaguchi T, Kitamoto T, Sato T, Mizusawa H, Nakamura Y, Noguchi M, Furukawa Y, Ishida C, Kuji I, Mitani K, Murayama S, Kohriyama T, Katayama S, Yamashita M, Yamamoto T, Udaka F, Kawakami A, Ihara Y, Nishinaka T, Kuroda S, Suzuki N, Shiga Y, Arai H, Maruyama M, Yamada M. MM2 type sporadic Creutzfeldt-Jakob disease: clinicoradiologic features and clinical diagnosis. International Symposium on Prion Diseases: Food and Drug Safety. Sendai Japan, October 31-November 2, 2004

9. Yanase D, Matsunari I, Yajima K, Chen W, Matsuda H, Yamada M. Assessment of normal aging on partial-volume effect corrected FDG PET. EANM’04 Annual Congress of The European Association of Nuclear Medicine. Helsinki, Finland, September 4-8, 2004

10. Yanase D, Matsunari I, Yajima K, Chen W, Matsuda H, Yamada M. Brain PET study of normal aging in Japanese: effect of atrophy correction. The 9th International Conference on Alzheimer’s Disease and Related Disorders. Philadelphia, Pennsylvania, USA, July 17-22, 2004